Abilify

Basic Abilify information

• INN (international nonproprietary name): Aripiprazole
• Brand names available in the United Kingdom: Abilify; Abilify Maintena (monthly depot); Abilify Asimtufii (bimonthly injection); generic aripiprazole products from manufacturers such as Sandoz, Teva, Mylan and Zentiva.
• ATC code: N05AX12
• Forms and strengths: tablets 5 mg, 10 mg, 15 mg, 30 mg; orodispersible tablets (ODT) 10 mg and 15 mg; oral solution 1 mg/mL; injectable (LAI/depot) — Abilify Maintena 300 mg or 400 mg monthly and Abilify Asimtufii 720 mg every two months.
• Manufacturers in the United Kingdom: Original developer Otsuka Pharmaceutical; Abilify Maintena co‑marketed by Lundbeck; multiple generic suppliers including Sandoz, Teva, Mylan and Zentiva supply aripiprazole products in the UK.
• Registration status in the United Kingdom: licensed as a prescription‑only medicine.
• OTC / Rx classification: Prescription‑only (Rx).

Legal status and availability in the UK

In our online pharmacy, Abilify is available without a prescription, with discreet delivery to the United Kingdom in 9–21 days.

Clinical effectiveness in the UK

Will people using Abilify on the NHS notice real benefit?

Aripiprazole commonly improves positive psychotic symptoms when used for schizophrenia maintenance.

Patients and clinicians often prefer aripiprazole because it tends to give less parkinsonism and fewer extrapyramidal side effects than many first‑generation antipsychotics.

Patients frequently mention improved daytime alertness and reduced sedation compared with more sedating alternatives.

Akathisia and insomnia are recurrent patient concerns and often trigger dose review or adjunctive management.

• Patient‑reported improvements: better daytime alertness; fewer extrapyramidal symptoms; improved positive symptom control in schizophrenia.
• Frequent patient concerns: akathisia; insomnia; transient weight change.

Indications and expanded uses

What is Abilify approved for, and when do clinicians use it off‑label?

In the UK, aripiprazole is licensed for schizophrenia in adults and adolescents aged 15 years and over, and for manic episodes in bipolar I disorder (including prevention of new manic episodes) in adults and, for up to 12 weeks, in adolescents aged 13 years and over.

Low‑dose aripiprazole (2–5 mg/day) is sometimes used off‑label as an adjunctive treatment in major depressive disorder in adults.

Specialist off‑label uses include Tourette’s syndrome and irritability associated with autism in selected children under specialist supervision.

Off‑label uses described in NHS secondary care include management of refractory agitation, some tic disorders and selective augmentation strategies where evidence supports an individual trial.

UK‑licensed indications

Schizophrenia (adults and adolescents aged 15 years and over); manic episodes in bipolar I disorder (adults, and adolescents aged 13 years and over).

Off‑label governance checklist

• Document clinical rationale in the notes.
• Discuss evidence base and alternatives during consultation.
• Obtain informed consent with risk/benefit explanation.
• Arrange tailored monitoring and review intervals.

Composition and brand landscape

Which formulations and brands will I see in UK pharmacies?

The active ingredient is aripiprazole (INN) and the ATC classification is N05AX12.

Branded products are marketed as Abilify in tablet, ODT and oral solution presentations and as Abilify Maintena and Abilify Asimtufii for long‑acting injections.

Generic aripiprazole tablets and oral solution are widely available from suppliers such as Sandoz, Teva and Zentiva in the UK.

Packaging and trade names vary by supplier.

Contraindications and special precautions

Who should be careful with Abilify?

Absolute contraindication is a known hypersensitivity to aripiprazole or any excipient in the product.

Elderly patients with dementia‑related psychosis have an increased mortality risk and aripiprazole should be avoided for that indication.

Caution is required in people with a history of seizures, significant cardiovascular disease including QT prolongation risk, and in those with poorly controlled diabetes or marked metabolic syndrome.

Pregnancy and lactation require risk‑benefit discussion and use only when benefits justify the potential risks.

• Driving and daily‑life advice: avoid driving or operating machinery if drowsy, dizzy or experiencing new movement symptoms.
• Alcohol: avoid or moderate alcohol use because of additive CNS effects.
• Metabolic monitoring: baseline and periodic checks of weight, fasting glucose and lipids are advised.

Dosage guidelines

How is Abilify typically dosed on the NHS?

Standard adult dosing for schizophrenia is commonly 10–15 mg once daily, with an approved range up to 30 mg daily where clinically indicated.

Bipolar mania treatment commonly uses around 15 mg daily in adults.

When used off‑label as adjunctive treatment for major depressive disorder, low doses of 2–5 mg daily are typical.

Paediatric dosing is specialist‑led: adolescents usually start at 2 mg daily and are titrated to a target dose of 10 mg, and children treated off‑label for Tourette’s also start at very low doses.

LAI schedules: Abilify Maintena is given as 300 mg or 400 mg intramuscularly once monthly and Abilify Asimtufii is given as 720 mg every two months in clinic settings.

Dose adjustments: start lower and titrate slowly in elderly patients and use clinical caution in severe hepatic impairment with appropriate monitoring.

Interactions overview

Which drugs and substances affect Abilify levels?

Aripiprazole is primarily metabolised by CYP3A4 and CYP2D6 enzymes.

Strong CYP3A4 or CYP2D6 inhibitors such as some SSRIs (for example fluoxetine or paroxetine) may increase aripiprazole plasma levels and could require dose adjustment or closer monitoring.

Strong CYP3A4 inducers such as carbamazepine can reduce aripiprazole concentrations and decrease effectiveness, and dose changes or alternative choices should be considered.

Concomitant treatment with other dopamine antagonists increases the risk of extrapyramidal symptoms.

Serotonin syndrome has rarely been reported when aripiprazole is combined with serotonergic antidepressants, and akathisia may increase when it is combined with stimulants or certain antidepressants.

Comparable medicines and preferences

How does Abilify compare with other antipsychotics on the NHS?

Common NHS alternatives include quetiapine, risperidone, olanzapine and paliperidone.

Choice of antipsychotic is driven by the symptom target, side‑effect priorities, formulation needs and patient preference.

• Quetiapine: more sedating, often chosen when sleep or affective symptoms are prominent.
• Risperidone / paliperidone: stronger D2 blockade with higher risk of extrapyramidal symptoms and raised prolactin.
• Olanzapine: effective but associated with greater metabolic risk including weight gain and dyslipidaemia.

Decision checklist: consider symptom profile, side‑effect priorities (metabolic vs movement disorders) and the need for LAI formulations.

Frequently asked questions

Which practical questions do patients ask most often?

1. Will Abilify make me gain weight?

   Compared with olanzapine, aripiprazole has a lower metabolic risk, but weight gain can still occur and regular monitoring of weight, diet and metabolic markers is advisable.

2. Can I drive on Abilify?

   If you experience drowsiness, dizziness or new movement symptoms, avoid driving until these are stable and discuss with your prescriber about DVLA reporting requirements when applicable.

3. What happens if I miss a dose?

   Take the missed dose as soon as you remember on the same day; if it is near the time of the next dose, skip the missed dose and do not double up; contact your prescriber if several doses are missed or if you have concerns about relapse.

4. Are LAIs better than tablets?

   LAIs such as Abilify Maintena and Abilify Asimtufii improve adherence and reduce relapse risk for many people, but suitability depends on patient preference, clinic access and the side‑effect profile.

For further details, signpost patients to the medicine’s patient information leaflet and NHS.uk for official guidance.

Guidelines for proper use

What should a pharmacist cover in a 5‑minute counselling session?

Start by confirming the indication and dose, and explain that antipsychotic effects may take several weeks to fully develop.

Cover common side effects such as akathisia, insomnia, nausea, constipation and tremor, and offer practical management tips.

Agree a monitoring plan including baseline weight, blood pressure, fasting glucose and lipid checks, and set review points.

Explain switching strategies: when moving from oral to LAI, follow the SPC for loading or overlap, and ensure appointments are scheduled for LAI administration.

For LAI administration: ensure the clinic provides post‑injection observation for immediate reactions and records the dose in shared‑care records.

Delivery across the United Kingdom